VRTX
Vertex Pharmaceuticals Incorporated
—
451.63 $
-7.3600 (%-1.60)
Previous Close: 458.99
Day Low₺450.39
Day High₺464.98
VRTX: Vertex Pharmaceuticals Incorporated Financials
VRTX Income Statement
Total revenue
Net income
Gross margin TTM
85.03%
Operating margin TTM
39.43%
Net profit margin TTM
32.74%
Return on investment TTM
—
| Period end | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 12,074,600,000 | 11,020,100,000 | 9,869,200,000 | 8,930,700,000 |
| Operating income | 4,760,700,000 | -232,900,000 | 3,832,000,000 | 4,307,400,000 |
| Net income | 3,953,200,000 | -535,600,000 | 3,619,600,000 | 3,322,000,000 |
All line items
| Line item | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 12,074,600,000 | 11,020,100,000 | 9,869,200,000 | 8,930,700,000 |
| Cost of revenue | 1,807,100,000 | 1,530,500,000 | 1,262,200,000 | 1,080,300,000 |
| Gross profit | 10,267,500,000 | 9,489,600,000 | 8,607,000,000 | 7,850,400,000 |
| Research and development expenses | 3,753,700,000 | 3,630,300,000 | 3,162,900,000 | 2,655,800,000 |
| General and administrative expenses | 0 | 0 | 0 | 0 |
| Selling and marketing expenses | 0 | 0 | 0 | 0 |
| Selling, general and administrative expenses | 1,753,100,000 | 1,464,300,000 | 1,136,600,000 | 944,700,000 |
| Other expenses | 0 | 4,627,900,000 | 475,500,000 | -57,500,000 |
| Operating expenses | 5,506,800,000 | 9,722,500,000 | 4,775,000,000 | 3,543,000,000 |
| Cost and expenses | 7,313,900,000 | 11,253,000,000 | 6,037,200,000 | 4,623,300,000 |
| Net interest income | 477,600,000 | 567,500,000 | 570,600,000 | 89,800,000 |
| Interest income | 490,900,000 | 598,100,000 | 614,700,000 | 144,600,000 |
| Interest expense | 13,300,000 | 30,600,000 | 44,100,000 | 54,800,000 |
| Depreciation and amortization | 207,200,000 | 205,800,000 | 181,300,000 | 148,300,000 |
| EBITDA | 4,863,700,000 | 486,300,000 | 4,605,200,000 | 4,435,500,000 |
| EBIT | 4,656,500,000 | 279,100,000 | 4,423,900,000 | 4,287,200,000 |
| Non-operating income (excl. interest) | 104,200,000 | -512,000,000 | -591,900,000 | 20,200,000 |
| Operating income | 4,760,700,000 | -232,900,000 | 3,832,000,000 | 4,307,400,000 |
| Total other income/expenses (net) | -117,500,000 | 481,400,000 | 547,800,000 | -75,000,000 |
| Income before tax | 4,643,200,000 | 248,500,000 | 4,379,800,000 | 4,232,400,000 |
| Income tax expense | 690,000,000 | 784,100,000 | 760,200,000 | 910,400,000 |
| Net income from continuing operations | 3,953,200,000 | -535,600,000 | 3,619,600,000 | 3,322,000,000 |
| Net income from discontinued operations | 0 | 0 | 0 | 0 |
| Other adjustments to net income | 0 | 0 | 0 | 0 |
| Net income | 3,953,200,000 | -535,600,000 | 3,619,600,000 | 3,322,000,000 |
| Net income deductions | 0 | 0 | 0 | 0 |
| Bottom line net income | 3,953,200,000 | -535,600,000 | 3,619,600,000 | 3,322,000,000 |
| EPS | 15 | -2 | 14 | 13 |
| Diluted EPS | 15 | -2 | 14 | 13 |
| Weighted average shares outstanding | 255,700,000 | 257,500,000 | 257,700,000 | 256,100,000 |
| Weighted average diluted shares outstanding | 258,000,000 | 257,900,000 | 260,500,000 | 259,100,000 |